Akero Therapeutics logo
Akero Therapeutics AKRO

Quarterly report 2025-Q3
added 11-07-2025

report update icon

Akero Therapeutics Total Assets 2011-2026 | AKRO

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.
Main categories of assets
Current assets (used within one year):
  • Cash and cash equivalents
  • Accounts receivable (amounts owed by customers)
  • Inventory of goods, raw materials, and supplies
  • Short-term investments
Non-current assets (used for more than one year):
  • Fixed assets (buildings, machinery, equipment)
  • Intangible assets (brands, patents, software)
  • Long-term investments
  • Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Akero Therapeutics

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
826 M 580 M 357 M 196 M 273 M 138 M 77.2 M 658 K - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
826 M 658 K 306 M

Quarterly Total Assets Akero Therapeutics

2025-Q3 2025-Q2 2024-Q4 2024-Q3 2024-Q2 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
1.01 B 1.11 B 826 M 818 M 865 M 580 M 635 M - 349 M 357 M 379 M - 170 M 196 M 224 M 238 M 258 M 273 M 273 M 273 M 273 M 138 M 138 M 138 M 138 M 77.2 M 77.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
1.11 B 77.2 M 392 M

Total Assets of other stocks in the Biotechnology industry

Issuer Total Assets Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
2.03 B - 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
396 M - 1052.0 % $ 415 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
783 M $ 1.68 2.44 % $ 429 M britainBritain
Acer Therapeutics Acer Therapeutics
ACER
11.6 M - 2.71 % $ 14 M usaUSA
Acasti Pharma Acasti Pharma
ACST
72 M - 4.01 % $ 150 M canadaCanada
Adverum Biotechnologies Adverum Biotechnologies
ADVM
180 M - - $ 86.2 M usaUSA
Kamada Ltd. Kamada Ltd.
KMDA
372 M $ 8.81 1.73 % $ 260 M israelIsrael
I-Mab I-Mab
IMAB
6.33 B - - $ 866 M chinaChina
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
778 M - - $ 1.01 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
18.1 B - - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
12 M - -13.47 % $ 169 M franceFrance
Adagene Adagene
ADAG
89.3 M $ 3.26 0.62 % $ 183 M chinaChina
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
41.4 M $ 3.28 -2.62 % $ 7.89 B australiaAustralia
Evogene Ltd. Evogene Ltd.
EVGN
39.9 M $ 0.81 -9.28 % $ 27.9 M israelIsrael
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
15.2 M - -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
14.8 M - -18.52 % $ 27.3 M britainBritain
Akouos Akouos
AKUS
279 M - 0.23 % $ 488 M usaUSA
Nymox Pharmaceutical Corporation Nymox Pharmaceutical Corporation
NYMX
654 K - -19.68 % $ 18.4 M canadaCanada
Albireo Pharma Albireo Pharma
ALBO
302 M - -0.23 % $ 916 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
16.1 M $ 0.79 -1.29 % $ 4.31 M chinaChina
Alpine Immune Sciences Alpine Immune Sciences
ALPN
287 M - - $ 2.17 B usaUSA
AlloVir AlloVir
ALVR
119 M - 4.14 % $ 49.1 M usaUSA
XTL Biopharmaceuticals Ltd. XTL Biopharmaceuticals Ltd.
XTLB
8.55 M $ 0.88 -1.43 % $ 442 M israelIsrael
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
34.8 M - 3.16 % $ 1.9 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
5.74 M - -11.43 % $ 502 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
109 M - -24.86 % $ 820 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
107 M - - $ 10.1 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
10.1 M - -45.71 % $ 1.2 M canadaCanada
Aravive Aravive
ARAV
62.2 M - -13.39 % $ 1.45 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
1.51 B - - - russiaRussia
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
1.3 B $ 224.42 -2.52 % $ 5 B danmarkDanmark
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
66.7 M - - $ 26.5 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
785 M - -6.81 % $ 3.04 B usaUSA
Athersys Athersys
ATHX
60.2 M - 3.77 % $ 22.4 M usaUSA
AVROBIO AVROBIO
AVRO
101 M - 1083.1 % $ 745 M usaUSA
Anavex Life Sciences Corp. Anavex Life Sciences Corp.
AVXL
104 M $ 4.13 0.12 % $ 352 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
35.1 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
12 M - -10.17 % $ 12.2 K usaUSA
Aytu BioScience Aytu BioScience
AYTU
124 M $ 2.36 2.27 % $ 14.8 M usaUSA
Aptinyx Aptinyx
APTX
66.7 M - -39.0 % $ 4.57 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
104 B - - $ 96.9 B britainBritain
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
14.7 M - 17.91 % $ 11.1 M usaUSA
Brickell Biotech Brickell Biotech
BBI
11.6 M - -5.38 % $ 6.06 M usaUSA
Codexis Codexis
CDXS
149 M $ 1.17 -0.85 % $ 85.9 M usaUSA
Athira Pharma Athira Pharma
ATHA
58.8 M - - $ 269 M usaUSA
BioNTech SE BioNTech SE
BNTX
22.5 B $ 110.12 -0.28 % $ 27.2 B germanyGermany
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
3.5 B $ 14.49 -0.75 % $ 4.48 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
47.1 M - 1.93 % $ 17.4 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
1.16 B - - $ 867 M germanyGermany